Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties

[Image: see text] In our continued effort to discover and develop best-in-class Bruton’s tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compounds that improved upon the druglike pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Med Chem Lett
Main Authors: Wang, Xiaojing, Barbosa, James, Blomgren, Peter, Bremer, Meire C., Chen, Jacob, Crawford, James J., Deng, Wei, Dong, Liming, Eigenbrot, Charles, Gallion, Steve, Hau, Jonathon, Hu, Huiyong, Johnson, Adam R., Katewa, Arna, Kropf, Jeffrey E., Lee, Seung H., Liu, Lichuan, Lubach, Joseph W., Macaluso, Jen, Maciejewski, Pat, Mitchell, Scott A., Ortwine, Daniel F., DiPaolo, Julie, Reif, Karin, Scheerens, Heleen, Schmitt, Aaron, Wong, Harvey, Xiong, Jin-Ming, Xu, Jianjun, Zhao, Zhongdong, Zhou, Fusheng, Currie, Kevin S., Young, Wendy B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2017
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467183/
https://ncbi.nlm.nih.gov/pubmed/28626519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.7b00103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados